[1] Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC public health. 2014;14(1):643.
[2] Morris MS. The role of B vitamins in preventing and treating cognitive impairment and decline. Advances in nutrition. 2012;3(6):801-12.
[3] Smith AD, Smith SM, De Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PloS one. 2010;5(9):e12244.
[4] Farina N, Jernerén F, Turner C, Hart K, Tabet N. Homocysteine concentrations in the cognitive progression of Alzheimer's disease. Experimental Gerontology. 2017;99:146-50.
[5] Pacheco-Quinto J, de Turco EBR, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels. Neurobiology of disease. 2006;22(3):651-6.
[6] Cascalheira JF, João SS, Pinhanços SS, Castro R, Palmeira M, Almeida S, et al. Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. Clinical biochemistry. 2009;42(9):783-90.
[7] Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Progress in neurobiology. 2019;174:53-89.
[8] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine. 2016;8(6):595-608.
[9] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
[10] Selkoe DJ. Alzheimer's disease: genotypes, phenotype, and treatments. Science. 1997;275(5300):630.
[11] Gispen WH, Biessels G-J. Cognition and synaptic plasticity in diabetes mellitus. Trends in neurosciences. 2000;23(11):542-9.
[12] Fraser ON, Bugnyar T. Ravens reconcile after aggressive conflicts with valuable partners. PLoS One. 2011;6(3).
[13] Pearson HA, Peers C. Physiological roles for amyloid β peptides. The Journal of physiology. 2006;575(1):5-10.
[14] Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, et al. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide. Nature. 1993;361(6409):260-3.
[15] Wilson CA, Doms RW, Lee VM. Intracellular APP Processing and A [beta] Production in Alzheimer Disease. Journal of Neuropathology & Experimental Neurology. 1999;58(8):787-94.
[16] Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nature reviews Molecular cell biology. 2007;8(2):101-12.
[17] Podolski IY, Podlubnaya Z, Kosenko E, Mugantseva E, Makarova E, Marsagishvili L, et al. Effects of Hydrated Forms of C60 Fullerene on Amyloid-Peptide Fibrillization In Vitro and Performance of the Cognitive Task. Journal of nanoscience and nanotechnology. 2007;7(4-5):1479-85.
[18] Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacology & therapeutics. 2000;88(2):93-113.
[19] Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31-9.
[20] Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Aβ clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer’s disease. Frontiers in aging neuroscience. 2013;5.
[21] Barros AS, Crispim RYG, Cavalcanti JU, Souza RB, Lemos JC, Cristino Filho G, et al. Impact of the Chronic Omega‐3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6‐Hydroxydopamine in Rats. Basic & Clinical Pharmacology & Toxicology. 2017;120(6):523-31.
[22] Laye S, Nadjar A, Joffre C, Bazinet RP. Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology. Pharmacological reviews. 2018;70(1):12-38.
[23] Echeverría F, Valenzuela R, Hernandez-Rodas MC, Valenzuela A. Docosahexaenoic acid (DHA), a fundamental fatty acid for the brain: New dietary sources. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2017;124:1-10.
[24] Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nature Reviews Neuroscience. 2014;15(12):771-85.
[25] Clifford JJ, Drago J, Natoli AL, Wong JY, Kinsella A, Waddington JL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington’s disease. Neuroscience. 2002;109(1):81-8.
[26] Grimm MO, Michaelson DM, Hartmann T. Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer’s disease: a rationale for multi-nutrient dementia prevention. Journal of Lipid Research. 2017;58(11):2083-101.
[27] Olivera‐Perez HM, Lam L, Dang J, Jiang W, Rodriguez F, Rigali E, et al. Omega‐3 fatty acids increase the unfolded protein response and improve amyloid‐β phagocytosis by macrophages of patients with mild cognitive impairment. The FASEB Journal. 2017;31(10):4359-69.
[28] Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. American journal of epidemiology. 2002;156(5):445-53.
[29] Richards M, Hardy R, Wadsworth ME. Does active leisure protect cognition? Evidence from a national birth cohort. Social science & medicine. 2003;56(4):785-92.
[30] Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of internal medicine. 2006;144(2):73-81.
[31] Geda YE, Roberts RO, Knopman DS, Christianson TJ, Pankratz VS, Ivnik RJ, et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Archives of neurology. 2010;67(1):80-6.
[32] Gómez-Pinilla F, Feng C. Molecular mechanisms for the ability of exercise supporting cognitive abilities and counteracting neurological disorders. Functional neuroimaging in exercise and sport sciences: Springer; 2012. p. 25-43.
[33] Leckie RL, Manuck SB, Bhattacharjee N, Muldoon MF, Flory JM, Erickson KI. Omega-3 fatty acids moderate effects of physical activity on cognitive function. Neuropsychologia. 2014;59:103-11.
[34] Köbe T, Witte AV, Schnelle A, Lesemann A, Fabian S, Tesky VA, et al. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment. Neuroimage. 2016;131:226-38.
[35] Chytrova G, Ying Z, Gomez-Pinilla F. Exercise contributes to the effects of DHA dietary supplementation by acting on membrane-related synaptic systems. Brain research. 2010;1341:32-40.
[36] Hosseinzadeh S, Roshan VD, Pourasghar M. Effects of intermittent aerobic training on passive avoidance test (shuttle box) and stress markers in the dorsal hippocampus of wistar rats exposed to administration of homocysteine. Iranian journal of psychiatry and behavioral sciences. 2013;7(1):37.
[37] Garekani ET, Mohebbi H, Kraemer RR, Fathi R. Exercise training intensity/volume affects plasma and tissue adiponectin concentrations in the male rat. Peptides. 2011;32(5):1008-12.
[38] Fathei M. The effect of eight weeks aerobic exercise on thyroid hormones in female rats with polycystic ovary syndrome. International journal of sport studies. 2014;4.
[39] Gama CS, Canever L, Panizzutti B, Gubert C, Stertz L, Massuda R, et al. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophrenia research. 2012;141(2-3):162-7.
[40] Ma H, Wang J, Wang J, Li Y, Li J. Fish oil ameliorates the allograft arteriosclerosis of intestine on rats. Pediatric transplantation. 2007;11(2):173-9.
[41] Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS letters. 2006;580(13):2994-3005.
[42] Kamat P, Vacek J, Kalani A, Tyagi N. Homocysteine induced cerebrovascular dysfunction: a link to Alzheimer’s disease etiology. The open neurology journal. 2015;9:9.
[43] Pi T, Liu B, Shi J. Abnormal Homocysteine Metabolism: An Insight of Alzheimer’s Disease from DNA Methylation. Behavioural Neurology. 2020;2020.
[44] Tawfik A, Mohamed R, Kira D, Alhusban S, Al-Shabrawey M. N-Methyl-D-aspartate receptor activation, novel mechanism of homocysteine-induced blood–retinal barrier dysfunction. Journal of Molecular Medicine. 2021;99(1):119-30.
[45] Oikonomidi A, Lewczuk P, Kornhuber J, Smulders Y, Linnebank M, Semmler A, et al. Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta. Journal of neurochemistry. 2016;139(2):324-32.
[46] Lin H-C, Hsieh H-M, Chen Y-H, Hu M-L. S-Adenosylhomocysteine increases β-amyloid formation in BV-2 microglial cells by increased expressions of β-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. Neurotoxicology. 2009;30(4):622-7.
[47] Zhang C-E, Wei W, Liu Y-H, Peng J-H, Tian Q, Liu G-P, et al. Hyperhomocysteinemia increases β-amyloid by enhancing expression of γ-secretase and phosphorylation of amyloid precursor protein in rat brain. The American journal of pathology. 2009;174(4):1481-91.
[48] Li JG, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β‐amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Annals of neurology. 2014;75(6):851-63.
[49] Uslu S, Akarkarasu ZE, Ozbabalik D, Ozkan S, Çolak O, Demirkan ES, et al. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer’s disease and vascular dementia. Neurochemical research. 2012;37(7):1554-9.
[50] Souza LC, Carlos Filho B, Goes AT, Del Fabbro L, de Gomes MG, Savegnago L, et al. Neuroprotective Effect of Physical Exercise in a Mouse Model of Alzheimer’s Disease Induced by β-Amyloid1–40 Peptide. Neurotoxicity research. 2013;24(2):148-63.
[51] Capetillo-Zarate E, Gracia L, Tampellini D, Gouras GK. Intraneuronal Aβ accumulation, amyloid plaques, and synapse pathology in Alzheimer’s disease. Neurodegenerative Diseases. 2012;10(1-4):56-9.
[52] Cavallucci V, D’Amelio M, Cecconi F. Aβ toxicity in Alzheimer's disease. Molecular neurobiology. 2012;45(2):366-78.
[53] Boyd-Kimball D, Mohmmad Abdul H, Reed T, Sultana R, Butterfield DA. Role of phenylalanine 20 in Alzheimer's amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity. Chemical research in toxicology. 2004;17(12):1743-9.
[54] Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, et al. Depletion of vitamin E increases amyloid β accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. Journal of Biological Chemistry. 2009;284(48):33400-8.
[55] Prediger RD, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G, et al. Differential susceptibility following β-amyloid peptide-(1–40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response. Behavioural brain research. 2007;177(2):205-13.
[56] Lee CD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. Journal of neural transmission. 2010;117(8):949-60.
[57] Agostinho P, A Cunha R, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Current pharmaceutical design. 2010;16(25):2766-78.
[58] Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Current drug targets. 2004;5(6):535-51.
[59] Paillard T, Rolland Y, de Souto Barreto P. Protective effects of physical exercise in Alzheimer's disease and Parkinson's disease: a narrative review. Journal of clinical neurology. 2015;11(3):212-9.
[60] Nalivaeva N, Belyaev N, Zhuravin I, Turner A. The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? International Journal of Alzheimer’s Disease. 2012;2012.
[61] Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Aβ by neprilysin. Science. 2001;292(5521):1550-2.
[62] Kang EB, Cho JY. Effects of treadmill exercise on brain insulin signaling and β-amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. Journal of Exercise Nutrition & Biochemistry. 2014;18(1):89.
[63] Liu H-l, Zhao G, Zhang H. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. Behavioural brain research. 2013;256:261-72.
[64] Kang E-B, Kwon I-S, Koo J-H, Kim E-J, Kim C-H, Lee J, et al. Treadmill exercise represses neuronal cell death and inflammation during Aβ-induced ER stress by regulating unfolded protein response in aged presenilin 2 mutant mice. Apoptosis. 2013;18(11):1332-47.
[65] Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, et al. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. International journal of molecular medicine. 2008;22(4):529-39.
[66] Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends in neurosciences. 2002;25(6):295-301.
[67] Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. The Journal of Neuroscience. 2005;25(17):4217-21.
[68] Lu B, Chow A. Neurotrophins and hippocampal synaptic transmission and plasticity. Journal of neuroscience research. 1999;58(1):76-87.
[69] Trejo JL, Carro E, Torres-Alemán I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. The Journal of neuroscience. 2001;21(5):1628-34.
[70] Nichol KE, Parachikova AI, Cotman CW. Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse. Behavioural brain research. 2007;184(2):124-32.
[71] Um HS, Kang EB, Cho IH, Kim CH, Cho JS, Hwang DY. The combination of exercise training and α-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice. International journal of molecular medicine. 2010;25(3):337-46.
[72] Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cellular signalling. 2010;22(7):977-83.
[73] Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation. 2008;5(13):2094-5.
[74] Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation. Neuroreport. 2008;19(13):1329-33.